Mandkind Pharma Ltd: Timeline

Date Major events
1991Inception of Mankind pharma Ltd
2004Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others
2005Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others
2007Entered the consumer healthcare segment with the launch of ‘Manforce’ brand Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst others * Raised ₹ 720 million from Monet Limited
2009 Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh
2010 Launched ‘Preganews’ brand in the consumer healthcare segment
2012 Setup first R&D centre at IMT Manesar, Haryana
2014Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan) Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
2015Incorporated Subsidiary, Lifestar Pharma LLC in the US Incorporated Subsidiary, Mankind Pharma Pte. Limited in Singapore
2017 Set up manufacturing facility in Sikkim
2018manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time
2019 Entered the female infertility segment with the launch of ‘Dydroboon’ tablets
2020Incorporated Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets
2021Incorporated Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE *Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets * Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets
2022Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited * Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others * Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others * Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories